Peter Hodder

发表

Table 2, Summary of Results

Peter Hodder, Scott Simanski, Franck Madoux, 2013 .

Table 1, Assay Summaries

Yongjun Wang, Michael D. Cameron, Becky A. Mercer, 2013 .

Figure 8, Probe development strategy, post-uHTS

Franck Madoux, Becky A. Mercer, Peter Hodder, 2014 .

[Table], Table of Assay Rationale and Screening Statistics

Becky A. Mercer, William R. Roush, Yongjun Wang, 2011 .

Probe Development Efforts to Identify Novel Inhibitors of ABHD10

Peter Hodder, Hugh Rosen, Jill Ferguson, 2013 .

[Table, SAR Tables].

Franck Madoux, Becky A. Mercer, Peter Hodder, 2011 .

[Table], Table of Assay Rationale and Description

Becky A. Mercer, Peter Hodder, Hugh Rosen, 2011 .

Table 2, Most promising leads from HTS Campaign for PAFAH2 inhibitor discovery

Peter Hodder, Hugh Rosen, Jill Ferguson, 2013 .

Figure 1, Alphascreen Technology

Franck Madoux, Michael D. Cameron, Becky A. Mercer, 2014 .

Figure 3, HCV Core dimerization HTS campaign overview

Qin Liu, Franck Madoux, Peter Chase, 2014 .

Table 6, Summary

Becky A. Mercer, Peter Hodder, Hugh Rosen, 2010 .

Table 3, Comparison of Current and Prior ROR Probes

Naresh Kumar, Michael D. Cameron, Becky A. Mercer, 2013 .

Figure 9, Structures of existing LYPLA1-inhibitors

Peter Hodder, Hugh Rosen, Jill Ferguson, 2013 .

Table 10, TCID50 Results (see AID 624575)

Franck Madoux, Michael D. Cameron, Becky A. Mercer, 2014 .

Table 3, Assay Rationale and Description

Dmitriy Minond, Becky A. Mercer, Peter Hodder, 2010 .

Table 3, Top HTS Hit from LYPLA1 Inhibitor Discovery Campaign

Peter Hodder, Hugh Rosen, Jill Ferguson, 2013 .

[Table], Summary Table of Screening Results

Franck Madoux, Michael D. Cameron, Becky A. Mercer, 2010 .

Table S5, SAR Analysis for Target: Ring-Constrained acetamides

Peter Hodder, Hugh Rosen, Jill Ferguson, 2011 .

[Table, Comparison to existing art and how the new probe is an improvement].

Liu Qin, Sa Saldanha, Becky A. Mercer, 2011 .

Table 4, Target SAR Analysis

Peter Hodder, Hugh Rosen, Jill Ferguson, 2013 .

[Table, Scientific Rationale for Project].

Becky A. Mercer, Peter Hodder, Hugh Rosen, 2010 .

Figure 2, IDE closed state, and open form of Pitrilysin

Franck Madoux, Becky A. Mercer, Peter Hodder, 2014 .

Table S2, SAR Analysis for Target: R2/R3 = cyclo

Peter Hodder, Hugh Rosen, Jill Ferguson, 2011 .

Figure 5, Probe development overview (post-HTS)

Franck Madoux, Michael D. Cameron, Becky A. Mercer, 2014 .

SAR Table 1, Lead scaffolds from the HTS campaign

Franck Madoux, Peter Chase, Michael D. Cameron, 2014 .

Table 1, Overview of PubChem assays for NOX1 inhibitor project

Hui Zhang, Peter Hodder, William R. Roush, 2011 .

Figure 4, Detailed experimental procedures for the preparation of ML311

Dmitriy Minond, Michael D. Cameron, Becky A. Mercer, 2013 .

Table 3.4-1, Target SAR Analysis

Peter Hodder, Hugh Rosen, Jill Ferguson, 2014 .

[Table], PMID List

Becky A. Mercer, Peter Hodder, Hugh Rosen, 2010 .

Figure 12, Probe dose-response curve, IDE inhibition (AID 624065, SID 136920229)

Franck Madoux, Becky A. Mercer, Peter Hodder, 2014 .

Table 4, Comparison of ML302 to existing Art

I Enogieru, Sa Saldanha, Becky A. Mercer, 2014 .

Table A3.2, Initial round of SAR by purchase with large structural modifications

Becky A. Mercer, Peter Hodder, Timothy P. Spicer, 2010 .

Table 1, IDE Inhibitor PubChem AIDs (click on hyperlink for details)

Franck Madoux, Becky A. Mercer, Peter Hodder, 2014 .

Table 5, Abbreviated SAR summary in the probe scaffold showing cell-free (biochemical) results

Franck Madoux, Becky A. Mercer, Peter Hodder, 2014 .

[Table, Chemical optimization of ML125].

Becky A. Mercer, William R. Roush, Yongjun Wang, 2011 .

Table 2, Top Inhibitors from 2ary Screen

Peter Hodder, Hugh Rosen, Jill Ferguson, 2013 .

Figure 1, IDE schematic structure

Franck Madoux, Becky A. Mercer, Peter Hodder, 2014 .

Table A2.1, Comparative data on similar compound structures establishing SAR (right-hand derivatization)

Becky A. Mercer, Peter Hodder, Timothy P. Spicer, 2010 .

Table 3, Hit summary, promiscuity analysis (reflects PubChem data available at time of uHTS)

Becky A. Mercer, Peter Hodder, A Zuhl, 2014 .

Table 4, Most potent scaffolds from the HTS campaign

Franck Madoux, Michael D. Cameron, Becky A. Mercer, 2014 .

Out of the laboratory and into the knowledge economy: A context for the evolution of New Zealand science centres

Peter Hodder, P. Hodder, 2010 .

Science as theatre: a New Zealand history of performances and exhibitions

Peter Hodder, P. Hodder, 2011 .